Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Citius Pharmaceuticals IncTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Schwab US Dividend Equity ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Schwab US Dividend Equity ETF trades at $34.26. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRSCHD
Market Cap
$18.73M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$34.27
52-Week Low
$0.48$26.44
Enterprise Value
$14.95M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

Schwab US Dividend Equity ETF

SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.

The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD